Feste Kombination aus Budesonid und Formoterol in der Erhaltungs- und Bedarfstherapie

Korn, Stephanie; Vogelmeier, Claus; Buhl, Roland

doi:10.1007/s00063-008-1050-y

Cited by 2 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[3] This option seems to be well tolerated and offers greater reductions in asthma exacerbations providing improved efficacy with a lower overall drug load in comparison with fixed-dose of each of these drugs. [4] This approach can also result in lower rate of hospitalization in uncontrolled asthma. [5] In this regard, for patients with poor asthma control, one of these two main options can be considered: Either an increase in dose of inhaled corticosteroids or the addition of a long-acting beta2-agonist that the latter regimen may be preferable.…”

Section: Introductionmentioning

confidence: 99%

Comparing clinical efficacy of Symbicort versus Pulmicort in reducing asthma symptom and improving its control

et al. 2014

View full text Add to dashboard Cite

Background:Recently, higher efficacy of the combination of long-acting beta2-adrenoceptor agonist and inhaled corticosteroids on controlling asthma symptoms has been hypothesized. This study aimed to examine the clinical effects of the combination of Budesonide with formoterol (Symbicort) and Budesonide (Pulmicort) alone in persistent asthma.Materials and Methods:In a randomized double-blinded clinical trial, 76 patients with definite diagnosis of moderate-to-severe asthma were randomized to receive Pulmicort 180 mcg/inhalation two puffs twice daily, or receive Symbicort 80/4.5 mg/inhalation two puffs twice daily, or receive Symbicort 160/4.5 mg/inhalation two puffs twice daily for 3 months. All participants were initially evaluated by spirometry for assessing respiratory parameters and also the level of asthma control was assessed by Asthma Control Test (ACT).Results:More significant improvement in spirometry parameters, including forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, as well as in peak expiratory flow (PEF) in both groups of Symbicort with the regimens 80/4.5 mg/inhalation or 160/4.5 mg/inhalation 2 puffs twice daily compared with Pulmicort group, ACT score was significantly improved in Symbicort group with the regimens 160/4.5 mg/inhalation compared with both Symbicort groups with lower dosage and Pulmicort group. Response to treatment in PEF parameter and also in ACT level was significantly more in those who received Symbicort with the regimens 160/4.5 mg/inhalation compared with other two interventional groups adjusted for gender and age.Conclusion:Symbicort with the regimens 160/4.5 mg/inhalation has higher efficacy in reducing asthma symptom and improving its control compared with low doses of this drug and with Pulmicort.

show abstract

Section: Introductionmentioning

confidence: 99%